Abstract Introduction Despite Tocilizumab is now recognized as a concrete therapeutic
option in patients with severe SARS-CoV-2 related respiratory failure, literature lacks about …

Background Data on the safety and efficacy profile of tocilizumab in patients with severe
COVID-19 needs to be enriched. Methods In this open label, prospective study, we …

Background Modulation of the immune system to prevent lung injury is being widely used
against the new coronavirus disease (COVID-19). The primary endpoint was mortality at 7 …

Introduction Tocilizumab is an interleukin 6 receptor antagonist which has been used for the
treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine …

Background This study aimed to evaluate the effectiveness of tocilizumab in mechanically
ventilated patients with coronavirus disease 2019 (COVID-19). Research design and …

Introduction Tocilizumab randomized clinical trial results are heterogeneous because of the
heterogenous population included in them. Methods We conducted a meta-analysis with …

Background Since the coronavirus disease 2019 (COVID-19) outbreak has rapidly
propagated with a high mortality rate, it is currently considered a global emergency …

Background The aim of this secondary analysis of the TESEO cohort is to identify, early in
the course of treatment with tocilizumab, factors associated with the risk of progressing to …

Introduction: Acute lung injury is associated with dysfunctional immune response to SARS-
CoV-2. This leads to CRS, which require immunomodulatory treatments aiming to limit the …

Objective Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …